SightfileU.S. market data from official filings

MAZE THERAPEUTICS INC (MAZE)

Name: MAZE THERAPEUTICS INC (MAZE) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001842295 · EDGAR filings · Updated 2026-07-02

MAZE THERAPEUTICS INC (MAZE) has reported institutional ownership of 93.4%, with 165 institutional managers holding positions valued at $1.54B per the latest 13F reporting period.

Institutional ownership

93.4%

Institutional managers

165

Reported 13F value

$1.54B

Insider activity

65 trans.

−$12.7M net selling

Latest updates

2026-07-02 — Insider transaction reported (Form 4)
2026-07-02 — Insider transaction reported (Form 4)
2026-07-01 — Notice of proposed sale filed (Form 144)
2026-07-01 — Insider transaction reported (Form 4)
2026-07-01 — Notice of proposed sale filed (Form 144)
2026-06-24 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, MAZE THERAPEUTICS INC has 165 institutional holders and institutional ownership of 93.4%.

Insider activity

Insiders reported 65 transactions (0 buys, 36 sells) across 7 reporting insiders, with a net reported value of −$12.7M.

Related companies

MBX BIOSCIENCES INC (MBX) · HARMONY BIOSCIENCES HLDGS IN (HRMY) · ANAPTYSBIO INC (ANAB) · ENOVIS CORPORATION COM (ENOV) · ESTABLISHMENT LABS HLDGS INC (ESTA) · OLEMA PHARMACEUTICALS INC (OLMA)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-02.